Stockreport

Vir Biotechnology Provides Updates on Chronic Hepatitis Delta and Oncology Programs and Upcoming 2026 Clinical Milestones [Yahoo! Finance]

Vir Biotechnology, Inc.  (VIR) 
PDF 88% of chronic hepatitis delta participants evaluable at 96 Weeks of treatment – New Phase 1 data from PSMA-targeted PRO-XTEN ® dual-masked T-cell engager VIR-5500 in pr [Read more]